Autolus Therapeutics (NASDAQ:AUTL) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Autolus Therapeutics (NASDAQ:AUTL) from a sell rating to a hold rating in a research report sent to investors on Sunday.

A number of other equities research analysts also recently weighed in on the stock. Weiss Ratings downgraded shares of Autolus Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 31st. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Autolus Therapeutics in a report on Monday, August 3rd. Finally, Jefferies Financial Group upgraded shares of Autolus Therapeutics to a “strong-buy” rating in a research report on Monday, April 20th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $10.00.

Autolus Therapeutics Stock Performance

Autolus Therapeutics stock opened at $2.15 on Friday. The business has a 50 day moving average price of $1.64 and a two-hundred day moving average price of $1.57. The company has a quick ratio of 4.40, a current ratio of 4.89 and a debt-to-equity ratio of 1.04. The stock has a market cap of $572.24 million, a price-to-earnings ratio of -2.03 and a beta of 2.07. Autolus Therapeutics has a 12 month low of $1.17 and a 12 month high of $2.43.

Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.06. The company had revenue of $45.69 million for the quarter, compared to analyst estimates of $38.56 million. Autolus Therapeutics had a negative return on equity of 178.66% and a negative net margin of 238.66%. As a group, equities analysts forecast that Autolus Therapeutics will post -0.8 EPS for the current year.

Institutional Trading of Autolus Therapeutics

Institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC grew its holdings in shares of Autolus Therapeutics by 115.6% in the 2nd quarter. GAMMA Investing LLC now owns 15,499 shares of the company’s stock worth $25,000 after purchasing an additional 8,309 shares during the last quarter. Independent Advisor Alliance bought a new position in Autolus Therapeutics during the 4th quarter valued at about $28,000. Marex Group plc bought a new position in Autolus Therapeutics during the 2nd quarter valued at about $28,000. Waverly Advisors LLC acquired a new position in Autolus Therapeutics in the first quarter valued at about $37,000. Finally, SmartHarvest Portfolios LLC acquired a new position in Autolus Therapeutics in the fourth quarter valued at about $43,000. Institutional investors and hedge funds own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.